Measurement of Cerebral Perfusion Indices from the Early Phase of [18F]MK6240 Dynamic Tau PET Imaging

Visual Abstract 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]MK6240) has high affinity and selectivity for hyperphosphorylated tau and readily crosses the blood–brain barrier. This study investigated whether the early phase of [18F]MK6240 can be used to provide a surrogate index of cerebral perfusion. Methods: Forty-nine subjects who were cognitively normal (CN), had mild cognitive impairment (MCI), or had Alzheimer’s disease (AD) underwent paired dynamic [18F]MK6240 and [11C]Pittsburgh compound B (PiB) PET, as well as structural MRI to obtain anatomic information. Arterial blood samples were collected in a subset of 24 subjects for [18F]MK6240 scans to derive metabolite-corrected arterial input functions. Regional time–activity curves were extracted using atlases available in the Montreal Neurologic Institute template space and using FreeSurfer. The early phase of brain time–activity curves was analyzed using a 1-tissue-compartment model to obtain a robust estimate of the rate of transfer from plasma to brain tissue, K1 (mL⋅cm−3⋅min−1), and the simplified reference tissue model 2 was investigated for noninvasive estimation of the relative delivery rate, R1 (unitless). A head-to-head comparison with R1 derived from [11C]PiB scans was performed. Grouped differences in R1 were evaluated among CN, MCI, and AD subjects. Results: Regional K1 values suggested a relatively high extraction fraction. R1 estimated noninvasively from simplified reference tissue model 2 agreed well with R1 calculated indirectly from the blood-based compartment modeling (r = 0.99; mean difference, 0.024 ± 0.027), suggesting that robust estimates were obtained. R1 measurements obtained with [18F]MK6240 correlated strongly and overall agreed well with those obtained from [11C]PiB (r = 0.93; mean difference, −0.001 ± 0.068). Statistically significant differences were observed in regional R1 measurements among CN, MCI, and AD subjects, notably in the temporal and parietal cortices. Conclusion: Our results provide evidence that the early phase of [18F]MK6240 images may be used to derive a useful index of cerebral perfusion. The early and late phases of a [18F]MK6240 dynamic acquisition may thus offer complementary information about the pathophysiologic mechanisms of the disease.

[1]  R. Boellaard,et al.  A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240 , 2021, EJNMMI Research.

[2]  A. Lammertsma,et al.  Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB , 2021, Molecular Imaging and Biology.

[3]  W. M. van der Flier,et al.  Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Özgür A. Onur,et al.  Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. Resnick,et al.  Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  C. Broeckhoven,et al.  18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O-H2O PET , 2019, Alzheimer's & Dementia.

[7]  Marc D. Normandin,et al.  Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  J. Berkhof,et al.  Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies , 2019, EJNMMI Research.

[9]  Sterling C. Johnson,et al.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.

[10]  R. Boellaard,et al.  Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies , 2019, PloS one.

[11]  R. Boellaard,et al.  Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease , 2019, EJNMMI Research.

[12]  S. Gauthier,et al.  In vivo quantification of neurofibrillary tangles with [18F]MK-6240 , 2018, Alzheimer's Research & Therapy.

[13]  Talakad G. Lohith,et al.  Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles , 2018, The Journal of Nuclear Medicine.

[14]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[15]  A. Drzezga,et al.  Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  N. Okamura,et al.  Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration , 2017, Journal of Alzheimer's disease reports.

[17]  G. Bormans,et al.  cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles. , 2017, Journal of labelled compounds & radiopharmaceuticals.

[18]  Keith A. Johnson,et al.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects , 2017, The Journal of Nuclear Medicine.

[19]  Anders Wall,et al.  Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Keith A. Johnson,et al.  Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. , 2016, JAMA neurology.

[21]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[22]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[23]  Frederik Barkhof,et al.  Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease , 2016, European Radiology.

[24]  Ove Almkvist,et al.  Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[25]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[26]  Oscar L Lopez,et al.  Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET , 2015, The Journal of Nuclear Medicine.

[27]  Maja A. A. Binnewijzend,et al.  Cerebral perfusion in the predementia stages of Alzheimer’s disease , 2015, European Radiology.

[28]  A. Gjedde,et al.  Blood-brain transfer of Pittsburgh compound B in humans , 2013, Front. Aging Neurosci..

[29]  Denise C. Park,et al.  Alterations in cerebral metabolic rate and blood supply across the adult lifespan. , 2011, Cerebral cortex.

[30]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[31]  Keith A. Johnson,et al.  Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly , 2011, Annals of neurology.

[32]  M. Hüll,et al.  Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.

[33]  J. Trojanowski,et al.  Distinct cerebral perfusion patterns in FTLD and AD , 2010, Neurology.

[34]  Gunnar Antoni,et al.  Unidirectional Influx and Net Accumulation of PIB , 2008, The open neuroimaging journal.

[35]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Alan A. Wilson,et al.  A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1) , 2004 .

[37]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[39]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[40]  Keith A. Johnson,et al.  Perfusion abnormalities in prodromal AD , 2000, Neurobiology of Aging.

[41]  J. Démonet,et al.  Age related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[42]  D. Berdichevsky,et al.  Improved Methods for Image Registration , 1996, NeuroImage.

[43]  Richard S. J. Frackowiak,et al.  Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. , 1990, Brain : a journal of neurology.

[44]  M. Mintun,et al.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  M. Raichle,et al.  Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  Salvatore Mazza,et al.  Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. , 2011, Journal of Alzheimer's disease : JAD.

[47]  Sterling C. Johnson,et al.  Effects of hypoperfusion in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[48]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.